Literature DB >> 22851861

Lentiviral vector-mediated down-regulation of IL-17A receptor in hepatic stellate cells results in decreased secretion of IL-6.

Sheng-Chu Zhang1, Yi-Hu Zheng, Pan-Pan Yu, Tan Hooi Min, Fu-Xiang Yu, Chao Ye, Yuan-Kang Xie, Qi-Yu Zhang.   

Abstract

AIM: To investigate the mechanism of interleukin (IL)-6 secretion through blocking the IL-17A/IL-17A receptor (IL-17RA) signaling pathway with a short hairpin RNA (shRNA) in hepatic stellate cells (HSCs) in vitro.
METHODS: HSCs were derived from the livers of adult male Sprague-Dawley rats. IL-6 expression was evaluated using real-time quantitative polymerase chain reaction and enzyme linked immunosorbent assay. The phosphorylation activity of p38 mitogen activated protein kinases (MAPK) and extracellular regulated protein kinases (ERK) 1/2 upon induction by IL-17A and suppression by IL-17RA shRNA were examined using Western blotting.
RESULTS: IL-6 expression induced by IL-17A was significantly increased compared to control in HSCs (P < 0.01 in a dose-dependent manner). Suppression of IL-17RA using lentiviral-mediated shRNA inhibited IL-6 expression induced by IL-17A compared to group with only IL-17A treatment (1.44 ± 0.17 vs 4.07 ± 0.43, P < 0.01). IL-17A induced rapid phosphorylation of p38 MAPK and ERK1/2 after 5 min exposure, and showed the strongest levels of phosphorylation of p38 MAPK and ERK1/2 at 15 min in IL-17A-treated HSCs. IL-6 mRNA expression induced by IL-17A (100 ng/mL) for 3 h exposure was inhibited by preincubation with specific inhibitors of p38 MAPK (SB-203580) and ERK1/2 (PD-98059) compared to groups without inhibitors preincubation (1.67 ± 0.24, 2.01 ± 0.10 vs 4.08 ± 0.59, P < 0.01). Moreover, Lentiviral-mediated IL-17RA shRNA 1 inhibited IL-17A-induced IL-6 mRNA expression compared to random shRNA in HSCs (1.44 ± 0.17 vs 3.98 ± 0.68, P < 0.01). Lentiviral-mediated IL-17RA shRNA 1 inhibited phosphorylation of p38 MAPK and ERK1/2 induced by 15 min IL-17A (100 ng/mL) exposure.
CONCLUSION: Down-regulation of the IL-17RA receptor by shRNA decreased IL-6 expression induced by IL-17A via p38 MAPK and ERK1/2 phosphorylation in HSCs. Suppression of IL-17RA expression may be a strategy to reduce the inflammatory response induced by IL-17A in the liver.

Entities:  

Keywords:  Hepatic stellate cells; Interleukin 17A; Interleukin 6; Liver fibrosis

Mesh:

Substances:

Year:  2012        PMID: 22851861      PMCID: PMC3406421          DOI: 10.3748/wjg.v18.i28.3696

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

Review 1.  T(H)-17 cells in the circle of immunity and autoimmunity.

Authors:  Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2007-04       Impact factor: 25.606

2.  T-helper 17 cell: A distinctive cell in liver diseases.

Authors:  Chao Ye; Wen-Yuan Li; Ming-Hua Zheng; Yong-Ping Chen
Journal:  Hepatol Res       Date:  2010-11-25       Impact factor: 4.288

3.  The interleukin-17 pathway is involved in human alcoholic liver disease.

Authors:  Arnaud Lemmers; Christophe Moreno; Thierry Gustot; Raphaël Maréchal; Delphine Degré; Pieter Demetter; Patricia de Nadai; Albert Geerts; Eric Quertinmont; Vincent Vercruysse; Olivier Le Moine; Jacques Devière
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

4.  TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

Authors:  Mandy J McGeachy; Kristian S Bak-Jensen; Yi Chen; Cristina M Tato; Wendy Blumenschein; Terrill McClanahan; Daniel J Cua
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

5.  Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B.

Authors:  Ji-Yuan Zhang; Zheng Zhang; Fang Lin; Zheng-Sheng Zou; Ruo-Nan Xu; Lei Jin; Jun-Liang Fu; Feng Shi; Ming Shi; Hui-Fen Wang; Fu-Sheng Wang
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

6.  Implication of Th17 and Th1 cells in patients with chronic active hepatitis B.

Authors:  Jian Ge; Kai Wang; Qing-Hua Meng; Zhao-Xia Qi; Fan-Li Meng; Yu-Chen Fan
Journal:  J Clin Immunol       Date:  2009-09-10       Impact factor: 8.317

7.  Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation.

Authors:  Devang N Patel; Carter A King; Steven R Bailey; Jeffrey W Holt; Kaliyamurthi Venkatachalam; Alok Agrawal; Anthony J Valente; Bysani Chandrasekar
Journal:  J Biol Chem       Date:  2007-07-25       Impact factor: 5.157

8.  IL-6 induces hepatic inflammation and collagen synthesis in vivo.

Authors:  I Choi; H S Kang; Y Yang; K H Pyun
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

Review 9.  Interleukin-17 family and IL-17 receptors.

Authors:  T A Moseley; D R Haudenschild; L Rose; A H Reddi
Journal:  Cytokine Growth Factor Rev       Date:  2003-04       Impact factor: 7.638

10.  Human IL-17: a novel cytokine derived from T cells.

Authors:  Z Yao; S L Painter; W C Fanslow; D Ulrich; B M Macduff; M K Spriggs; R J Armitage
Journal:  J Immunol       Date:  1995-12-15       Impact factor: 5.422

View more
  3 in total

1.  Small interfering RNA targeting receptor for advanced glycation end products suppresses the generation of proinflammatory cytokines.

Authors:  Xiao-Wei Wang; Wei-Dong Li; Jin-Rong Xia; Zhan Li; Xiao-Gang Cai
Journal:  Exp Ther Med       Date:  2015-06-11       Impact factor: 2.447

2.  Expression of recombinant Schistosoma japonicum protein rSjE16 and its effects on LX-2 cells in vitro.

Authors:  Wenxi Gao; Wenxia Peng; Xingpei Ji; Dandan Zhu; Jinling Chen; Jinrong Feng; Yang Yu; Lian Duan; Yinong Duan
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

3.  FTO promotes liver inflammation by suppressing m6A mRNA methylation of IL-17RA.

Authors:  Xiaojie Gan; Zhihui Dai; Chunmei Ge; Haozan Yin; Yuefan Wang; Jian Tan; Shuhan Sun; Weiping Zhou; Shengxian Yuan; Fu Yang
Journal:  Front Oncol       Date:  2022-09-12       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.